Atlas Trials

Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

Clinical trial NCT06851221 · COMPLETED

Trial details

NCT number
NCT06851221
Sponsor
Meyer Children's Hospital IRCCS
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
NeuroblastomaEwing Sarcoma
Start date
2020-08-05
Primary completion
2024-03-05
Enrollment
95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.